Dublin, Sept. 12, 2017 -- The "United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, Prostate) Infectious Diseases Test (Virology, HPV, HAI, Critical Care) Genetic Test (Blood Screening, Food Pathogen, Tissue Typing HLA)" report has been added to Research and Markets' offering.
By 2024, the United States molecular diagnostics market is expected to cross US$ 9 billion
Main factors pouring the growth of molecular diagnostics market are increased incidence of infectious diseases and different types of cancer. On the other hand, advancement of new technologies in the field of medicine and research fuels the molecular diagnostics market.
A diagnosis based on symptoms and use of substitute markers is replaced by the genomic and the proteomic analysis. Molecular diagnostics system is one of the promising systems which can transform disease diagnosis. It offers the assurance for early disease detection, potentially before symptoms have even occurred.
Molecular oncology tests have emerged as a substantial market segment. Today in the field of medical diagnostics, molecular diagnostics for cancer testing offers one of the key areas for innovation and expansion. The United States leads the regional market for blood screening and blood products. Molecular diagnostics is also a significant tool for Food Pathogen Detection Testing and HLA Testing as well as other diseases.
United State Molecular Diagnostics Market Analysis
United States molecular diagnostics market has been classified into three main categories: Oncology Test, Infectious Disease Test and Genetic Disease Test. Oncology Test has been classified into four main categories: Breast Cancer Test, Colorectal Cancer Test, Prostate Cancer Test and Other Cancer Test. Infectious Disease Test has been classified into four main categories, namely, Virology, HAI, HPV and Critical Care Test and Genetic Test has been segmented into Blood Screening, HLA and Food Pathogen Test.
United State Molecular Diagnostics Market Shares: Overview
According to this report, In the United States Molecular Diagnostics Market, Infectious Test market and the Oncology Test both have a significant market. In Molecular Oncology Test market; Breast cancer is dominating the market while in Molecular Infectious test market; Virology leads all other segments. In the area of Tests Volume; Genetics test drives all way ahead from Infectious and Oncology Test owing to Food Pathogen Test Volume.
Key Players in the United State Molecular Diagnostics Market
This report describes the players and in-depth analysis of these players, the players who played a very vital role in the development of molecular diagnostics in the United State are Roche, Hologic, Becton Dickinson, Myraid Genetics, Qiagen, Abbott, Siemens, bioMrieux and Cepheid.
United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, and Prostate) Infectious Diseases Test (Virology, HPV, HAI, and Critical Care) Genetic Test (Blood Screening, Food Pathogen, and Tissue Typing HLA) provides a comprehensive assessment of the fast-evolving, high-growth United States Molecular Diagnostics Market. This is the 2nd edition of the report.
This 146 page report with 87 Figures and 4 Tables studies the United States Molecular Diagnostics from 4 view points:
1) Molecular Diagnostics Market and Forecast
2) Segments Market & Forecast
3) Segments Test Volume & Forecast
4) Company Molecular Diagnostics Sales & Forecast
United States Molecular Diagnostics Market & Test Volume - Application Segment Analysis (2010 - 2024):
- Oncology Test
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
- Infectious Diseases
- Virology Test
- HPV Test
- HAI Test
- Critical Care Test
- Genetic Test
- Blood Screening
- Food Pathogen Test
- Tissue Typing (HLA Test)
Company Sales Analysis (2010 - 2024):
1. Roche
2. Abbott
3. Myriad Genetics
4. BioMerieux
5. Qiagen
6. Hologic Inc.
7. Becton Dickinson
8. Siemens
9. Cepheid
10. Others
For more information about this report visit https://www.researchandmarkets.com/research/9526bh/united_states
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Genomics, Women's Health, Infectious Disease Testing, Blood Banking, Intensive Care and Emergency Medicine , Food Additives


Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Apple Turns 50: From Garage Startup to AI Crossroads
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
First Western Ship Transits Strait of Hormuz Since Iran War Began
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 



